AbbVie Aktie News

Some decisions are tough to make. Others are so easy that they don't require much thought and are practically no-brainers.

AbbVie (ABBV -0.36%) is a drug company, spun off from Abbott Laboratories in 2013, that you might want to consider for your long-term portfolio. One of the biggest green flags for investing in the company is its dividend.

The company is dealing with declining sales of its former cash-cow drug Humira.

You probably exercise significantly more caution before investing a lot of money than you do when investing a small amount. The more money at risk, the more risk-averse most of us become.

Abbvie Inc (NYSE:ABBV) shares moved higher after the pharma company announced it has secured extended patent protection for its blockbuster autoimmune drug RINVOQ (upadacitinib). It said in a regulatory filing that it has reached settlements with all generic manufacturers that had filed applications to produce generic versions of RINVOQ, effectively extending US patent protection until April 20...

AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, according to some analysts.

The biopharmaceutical company doesn't expect U.S. generic entry for the drug before 2037 now that it has settled litigation.

Shares of AbbVie (ABBV 3.95%) were jumping 4.2% higher as of 11:37 a.m. ET on Thursday.